Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Biocept stock in Canada | $4.48

Own Biocept shares in just a few minutes.

Updated . What changed?

Fact checked

Biocept, Inc is a diagnostics & research business based in the US. Biocept shares (BIOC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.48 – a decrease of 4.68% over the previous week. Biocept employs 88 staff and has a trailing 12-month revenue of around $10.7 million.

How to buy shares in Biocept

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BIOC in this case.
  5. Research Biocept shares. The platform should provide the latest information available.
  6. Buy your Biocept shares. It's that simple.

How has Coronavirus impacted Biocept's share price?

Since the stock market crash in March caused by coronavirus, Biocept's share price has had significant positive movement.

Its last market close was $4.48, which is 92.70% up on its pre-crash value of $0.327 and 2,021.21% up on the lowest point reached during the March crash when the shares fell as low as $0.2112.

If you had bought $1,000 worth of Biocept shares at the start of February 2020, those shares would have been worth $982.68 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $14,923.37.

Biocept share price

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

Information last updated 2020-12-02.
Latest market close $4.48
52-week range $2.112 - $15.9
50-day moving average $4.6011
200-day moving average $5.8505
Wall St. target price $20
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.631

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Buy and sell thousands of US and Canadian stocks and ETFs commission-free with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
loading

Compare up to 4 providers

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biocept price performance over time

Historical closes compared with the last close of $4.48

1 week (2020-11-25) -0.22%
1 month (2020-11-02) 2.99%
3 months (2020-09-02) 622.11%
6 months (2020-06-02) 971.77%
1 year (2019-12-02) 749.93%
2 years (2018-11-30) 322.64%
3 years (2017-12-01) 540.00%
5 years (2015-12-02) 142.16%

Biocept financials

Revenue TTM USD$10.7 million
Gross profit TTM USD$-5,448,954
Return on assets TTM -60.98%
Return on equity TTM -174.97%
Profit margin -236.84%
Book value $1.594
Market capitalisation USD$61.4 million

TTM: trailing 12 months

How to short and sell Biocept shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BIOC.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 369,103 Biocept shares held short by investors – that's known as Biocept's "short interest". This figure is 7.1% down from 397,453 last month.

There are a few different ways that this level of interest in shorting Biocept shares can be evaluated.

Biocept's "short interest ratio" (SIR)

Biocept's "short interest ratio" (SIR) is the quantity of Biocept shares currently shorted divided by the average quantity of Biocept shares traded daily (recently around 485661.84210526). Biocept's SIR currently stands at 0.76. In other words for every 100,000 Biocept shares traded daily on the market, roughly 760 shares are currently held short.

However Biocept's short interest can also be evaluated against the total number of Biocept shares, or, against the total number of tradable Biocept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biocept's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Biocept shares in existence, roughly 30 shares are currently held short) or 0.0276% of the tradable shares (for every 100,000 tradable Biocept shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biocept.

Find out more about how you can short Biocept stock.

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:10 basis on 8 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as $2.112 up to $15.9. A popular way to gauge a stock's volatility is its "beta".

BIOC.US volatility(beta: 0.9)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.9008. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site